$AADI
Aadi Bioscience, Inc.

2017 Form 10-K Financial Statement

#000156459018005868 Filed on March 15, 2018

View on sec.gov

Income Statement

Concept 2017 2016 Q4 2016 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.241M $1.310M $1.260M
YoY Change 75.49%
% of Gross Profit
Research & Development $12.15M $1.990M $3.480M
YoY Change 6.86%
% of Gross Profit
Depreciation & Amortization $51.27K $20.00K $10.00K
YoY Change -26.42%
% of Gross Profit
Operating Expenses $21.39M $3.305M $4.745M
YoY Change 28.59%
Operating Profit -$21.39M -$3.305M -$4.745M
YoY Change 28.59%
Interest Expense -$105.8K -$230.0K -$170.0K
YoY Change -78.06%
% of Operating Profit
Other Income/Expense, Net -$12.06K -$212.6K -$140.3K
YoY Change -96.55%
Pretax Income -$21.40M -$3.520M -$4.890M
YoY Change 26.01%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$21.40M -$3.518M -$4.886M
YoY Change 26.01%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$11.86M -$2.53 -$3.29
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2017 2016 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.26M
YoY Change 1120.96%
Cash & Equivalents $20.26M $1.610M
Short-Term Investments $0.00
Other Short-Term Assets $635.4K $209.0K
YoY Change 12.96%
Inventory
Prepaid Expenses $353.4K
Receivables $0.00 $4.157K
Other Receivables $0.00
Total Short-Term Assets $20.90M $2.226M
YoY Change 838.75%
LONG-TERM ASSETS
Property, Plant & Equipment $107.2K $149.6K
YoY Change -28.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.96K
YoY Change 0.0%
Total Long-Term Assets $128.2K $170.6K
YoY Change -24.85%
TOTAL ASSETS
Total Short-Term Assets $20.90M $2.226M
Total Long-Term Assets $128.2K $170.6K
Total Assets $21.03M $2.397M
YoY Change 777.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.277M $1.136M
YoY Change 12.41%
Accrued Expenses $2.316M
YoY Change 73.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.592M $14.86M
YoY Change -75.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.592M $14.86M
Total Long-Term Liabilities $0.00
Total Liabilities $3.592M
YoY Change -75.82%
SHAREHOLDERS EQUITY
Retained Earnings -$86.22M
YoY Change
Common Stock $124.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.44M -$86.22M
YoY Change
Total Liabilities & Shareholders Equity $21.03M $2.397M
YoY Change 777.29%

Cashflow Statement

Concept 2017 2016 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$21.40M -$3.518M -$4.886M
YoY Change 26.01%
Depreciation, Depletion And Amortization $51.27K $20.00K $10.00K
YoY Change -26.42%
Cash From Operating Activities -$18.88M -$3.040M -$4.830M
YoY Change 20.14%
INVESTING ACTIVITIES
Capital Expenditures $8.896K $0.00 $0.00
YoY Change -92.15%
Acquisitions
YoY Change
Other Investing Activities $50.00K
YoY Change
Cash From Investing Activities $41.10K $0.00 $0.00
YoY Change -136.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $40.25M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 37.50M 3.350M 4.530M
YoY Change 204.93%
NET CHANGE
Cash From Operating Activities -18.88M -3.040M -4.830M
Cash From Investing Activities 41.10K 0.000 0.000
Cash From Financing Activities 37.50M 3.350M 4.530M
Net Change In Cash 18.65M 310.0K -300.0K
YoY Change -627.78%
FREE CASH FLOW
Cash From Operating Activities -$18.88M -$3.040M -$4.830M
Capital Expenditures $8.896K $0.00 $0.00
Free Cash Flow -$18.89M -$3.040M -$4.830M
YoY Change 19.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12147132
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9241411
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
25952620
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
3606
CY2016Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
8434
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3606
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
8434
CY2017Q4 arpo Deferred Tax Assets And Liabilities Net Before Valuation Allowance
DeferredTaxAssetsAndLiabilitiesNetBeforeValuationAllowance
22169464
CY2016Q4 arpo Deferred Tax Assets And Liabilities Net Before Valuation Allowance
DeferredTaxAssetsAndLiabilitiesNetBeforeValuationAllowance
25944186
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22169464
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
25944186
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-3774722
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6334258
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
4759585
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
5583862
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
4756238
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
6288858
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4759585
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5583862
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4756238
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-6288858
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-236118
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
63555
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
106671
CY2017Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
53829
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-4995703
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-5520307
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-4649567
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-6235029
CY2017Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
943297
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5939000
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5520307
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4649567
CY2017Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6235029
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5605151
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26895164
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26926673
CY2017Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26965293
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.06
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
4205443
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
4377433
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
4745315
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
3305394
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4205443
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4377433
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4745315
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3305394
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10745
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7829
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-140286
CY2016Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-212556
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-4194698
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-4385262
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-4885601
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-3517950
CY2016Q2 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
224224
CY2016Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1015371
CY2016 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
658102
CY2016 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
82818
CY2016Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1028121
CY2016Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1054657
CY2016Q4 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1054652
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5210069
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5189159
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5940258
CY2016Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4572602
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
737016
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
823097
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18968
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
488326
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
74701187
CY2017 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
13447934
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37163390
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
36101
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
649409
CY2017 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3084385
CY2017 us-gaap Depreciation
Depreciation
51268
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
888094
CY2016Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
961482
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.07
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.30
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.69
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.76
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
208478
CY2016 us-gaap Depreciation
Depreciation
69673
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
649409
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
488326
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017Q2 dei Entity Public Float
EntityPublicFloat
0
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27140969
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1609694
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
50000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4157
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
313140
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
353434
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
322221
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
209038
CY2017Q4 us-gaap Assets Current
AssetsCurrent
20899470
CY2016Q4 us-gaap Assets Current
AssetsCurrent
2226323
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
107223
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
149595
CY2017Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
20960
CY2016Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
20960
CY2017Q4 us-gaap Assets
Assets
21027653
CY2016Q4 us-gaap Assets
Assets
2396878
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3592164
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2470970
CY2016Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
12386647
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3592164
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14857617
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
73757890
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108562656
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
17435489
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21027653
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27070038
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27070038
CY2017 us-gaap Operating Expenses
OperatingExpenses
21388543
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-21388543
CY2017 arpo Grant Income
GrantIncome
93719
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
997
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-349926
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-16983511
CY2016 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
224224
CY2017 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
943297
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21673349
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
75561
CY2016 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
188686
CY2017 us-gaap Paid In Kind Interest
PaidInKindInterest
204929
CY2016 us-gaap Paid In Kind Interest
PaidInKindInterest
2823
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4157
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-114359
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
72889
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-90404
CY2017 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
1604636
CY2016 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
311096
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18883535
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15718144
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8896
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
113297
CY2017 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
50000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
41104
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-113297
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
36100
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
18968
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
297354
CY2016 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
12542203
CY2016 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
264247
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40247777
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
37496846
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12296924
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
18654415
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3534517
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5144211
CY2017 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
74701187
CY2017 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
13447934
CY2016 arpo Extinguishment Of Preferred Stock
ExtinguishmentOfPreferredStock
224224
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
214595
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
76650
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
65890
CY2017Q4 arpo Operating Leases Future Minimum Payments Due In Two Years And Thereafter
OperatingLeasesFutureMinimumPaymentsDueInTwoYearsAndThereafter
10760
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2016Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
0
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: fair value of the Company&#8217;s stock-based awards. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically, the Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, <font style="font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</font>, to estimate the fair value of its common stock. Each valuation methodology included estimates and assumptions that required the Company&#8217;s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of redeemable convertible preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time, and, at December&#160;31, 2016, a probability analysis of various liquidity events under differing scenarios, including both a potential public trading scenario and potential sale scenario. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s results can also be affected by economic, political, legislative, regulatory, and legal actions. Economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, government fiscal policies, and changes in the prices of research studies, can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities and carries various levels of insurance, the Company could be affected by civil, criminal, regulatory or administrative actions, claims, or proceedings. </p></div>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Off-Balance Sheet Risk </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents and short-term investments are the only financial instruments that potentially subject the Company to concentrations of credit risk. At December 31, 2017 and 2016, all the Company&#8217;s cash and cash equivalents were deposited in accounts at two principal financial institutions. The Company maintains its cash and cash equivalents and short-term investments with a high-quality, accredited financial institution and, accordingly, such funds are subject to minimal credit risk. The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements. </p></div>
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
124
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
125995438
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-86218629
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2396878
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
17440436
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1240925
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1240925
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
2707
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20264109
CY2017 dei Entity Registrant Name
EntityRegistrantName
Aerpio Pharmaceuticals, Inc.
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
317562
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11367590
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5265995
CY2016 us-gaap Operating Expenses
OperatingExpenses
16633585
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-16633585
CY2016 arpo Grant Income
GrantIncome
131281
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-105782
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-482204
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12063
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-21400606
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001422142
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Document Type
DocumentType
10-K
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Trading Symbol
TradingSymbol
ARPO
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-86218753
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q1 arpo Capital Stock Conversion Basis Ratio
CapitalStockConversionBasisRatio
2.3336572
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2016Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2016 arpo Capital Stock Conversion Basis Ratio
CapitalStockConversionBasisRatio
2.3336572
CY2017Q4 arpo Number Of Financial Institutions
NumberOfFinancialInstitutions
2
CY2016Q4 arpo Number Of Financial Institutions
NumberOfFinancialInstitutions
2
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1276537
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1135608
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
277217
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
200468
CY2017Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
833650
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
483442
CY2017Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
69549
CY2016Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
52835
CY2017Q4 arpo Accrued Project Costs Current
AccruedProjectCostsCurrent
1069852
CY2016Q4 arpo Accrued Project Costs Current
AccruedProjectCostsCurrent
541158
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
65359
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
57459
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
443068
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
445310
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
335845
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
295715
CY2017 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2017Q4 arpo Number Of Shares Of Common Stock In Lock Up Agreements
NumberOfSharesOfCommonStockInLockUpAgreements
18900000
CY2017 arpo Restricted Period For Shares Of Common Stock In Lock Up Agreements
RestrictedPeriodForSharesOfCommonStockInLockUpAgreements
P9M
CY2017 arpo Restricted Percentage Of Common Stock For Holders Of Specified Shares
RestrictedPercentageOfCommonStockForHoldersOfSpecifiedShares
0.80
CY2017Q4 arpo Number Of Shares Of Common Stockholders With Specified Percentage Restriction
NumberOfSharesOfCommonStockholdersWithSpecifiedPercentageRestriction
915000
CY2017 arpo Period Agreed By Common Stockholder Not To Effect Short Sale After Merger
PeriodAgreedByCommonStockholderNotToEffectShortSaleAfterMerger
P12M
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.00
CY2017 arpo Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P3Y
CY2017 arpo Class Of Warrant Or Right Expiration Date
ClassOfWarrantOrRightExpirationDate
2020-03-15
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
4152801
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22343903
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20912088
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.03
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-24.52
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
852665
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-66554755
CY2017 arpo Redeemable Convertible Preferred Stock Voting Rights
RedeemableConvertiblePreferredStockVotingRights
The holders of redeemable convertible preferred stock were entitled to the number of votes equal to the number of whole shares of Aerpio common stock into which the shares of redeemable convertible preferred stock were convertible. Except as provided by law or otherwise, the holders of redeemable convertible preferred stock voted together with the holders of Aerpio common stock as a single class. Certain significant actions required approval by at least 50% of the holders of redeemable convertible preferred stock voting as a single class on an as converted basis.
CY2017 arpo Redeemable Convertible Preferred Stock Conversion Percentage
RedeemableConvertiblePreferredStockConversionPercentage
1
CY2017 arpo Number Of Option Awards Granted
NumberOfOptionAwardsGranted
5
CY2016 arpo Number Of Option Awards Granted
NumberOfOptionAwardsGranted
1
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
907485
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
50228
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
21870
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
8251
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
927592
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
312547
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
615045
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1014018
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
25729
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2901
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1912980
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1161495
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
751485
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.66
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.80
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.87
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
1.24
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.70
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.82
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.63
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.50
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.40
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.11
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.72
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.02
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.69
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M23D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y7M6D
CY2016 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P6Y11M1D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M27D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y7M24D
CY2017 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P6Y0M26D
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
135711
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1030217
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
308767
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
721451
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2738704
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
441553
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2297151
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.39
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
92544
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
20335
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3517806
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.39
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.22
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M8D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0219
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0139
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6757
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6100
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0083
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0083
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0172
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0377
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0142
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0132
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1764
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.3728
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.5277
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18819077
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
23146178
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
204599
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
18400
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
96578
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
96570
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3038863
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2670688
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
13953
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
20784
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22173070

Files In Submission

Name View Source Status
0001564590-18-005868-index-headers.html Edgar Link pending
0001564590-18-005868-index.html Edgar Link pending
0001564590-18-005868.txt Edgar Link pending
0001564590-18-005868-xbrl.zip Edgar Link pending
arpo-10k_20171231.htm Edgar Link pending
arpo-20171231.xml Edgar Link completed
arpo-20171231.xsd Edgar Link pending
arpo-20171231_cal.xml Edgar Link unprocessable
arpo-20171231_def.xml Edgar Link unprocessable
arpo-20171231_lab.xml Edgar Link unprocessable
arpo-20171231_pre.xml Edgar Link unprocessable
arpo-ex1015_878.htm Edgar Link pending
arpo-ex231_879.htm Edgar Link pending
arpo-ex311_9.htm Edgar Link pending
arpo-ex312_8.htm Edgar Link pending
arpo-ex321_7.htm Edgar Link pending
arpo-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2018031520514540611262.jpg Edgar Link pending
g2018031520514541211263.jpg Edgar Link pending
g2018031520514542511264.jpg Edgar Link pending
g2018031520514543311265.jpg Edgar Link pending
g2018031520514543611266.jpg Edgar Link pending
g2018031520514544511267.jpg Edgar Link pending
g2018031520514545211268.jpg Edgar Link pending
g2018031520514546011269.jpg Edgar Link pending
g2018031520514547311270.jpg Edgar Link pending
g2018031520514548311271.jpg Edgar Link pending
g2018031520514549411272.jpg Edgar Link pending
g2018031520514604511273.jpg Edgar Link pending
g2018031520514605211274.jpg Edgar Link pending
g2018031520514606011275.jpg Edgar Link pending
g2018031520514607411276.jpg Edgar Link pending
g2018031520514608011277.jpg Edgar Link pending
g2018031520514608911278.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending